Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Gossamer Bio, Inc.GOSS · Entity 6928 | EVP, Tech Ops and Admin | August 24, 2026 | August 26, 2026 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director | January 30, 2026 | February 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Gossamer Bio, Inc.
Report date August 24, 2026 · Filed August 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.18 · Expires 2036-08-23 | Direct | 2,900,026 |
Reported balance
After 2026-08-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-24 · Grant · Acquired 2,900,026 · Balance 2,900,026 F1: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date.
HERON THERAPEUTICS, INC. /DE/
Report date January 30, 2026 · Filed February 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 53,960 |
Reported balance
After 2026-01-30 transaction · row 1
1 source rowRow 1 · 2026-01-30 · Grant · Acquired 53,960 · Balance 53,960 F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 24, 2026 Filed Aug 26, 2026 22:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 2,900,026 | $0.00 Strike: $0.18 | $0.00 |
DisclosureSEC source: 0001553179-26-000005 · wk-form4_1787782397.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,900,026 Underlying: Common Stock · 2,900,026 shares Expires 2036-08-23 F1 · derivative.exercise_date: 50% of the total number of shares subject to the option will vest upon FDA approval of seralutinib, and 1/24th of the remaining 50% of the total number of shares subject to the option will vest on the last day of each one-month period after such FDA approval, in each case subject to the Reporting Person's continuous service to the Issuer on each such vesting date. To the extent FDA approval of seralutinib does not occur on or prior to the date that is two years following the grant date of the option, 1/24th of the total number of shares subject to the option will vest on the last day of each one-month period following the date that is two years following the grant date of the option, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 20 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-03-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 47,667 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 19 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,667 Underlying: Common Stock · 47,667 shares Expires 2030-02-14 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 18 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 126,667 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 17 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,667 Underlying: Common Stock · 126,667 shares Expires 2032-01-05 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 157,500 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 16 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2032-12-06 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 157,500 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 15 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2033-03-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 14 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-11-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 375,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 13 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2034-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 440,000 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 12 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2035-03-03 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 506,250 | Not disclosed Strike: $0.45 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 11 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,250 Underlying: Common Stock · 506,250 shares Expires 2036-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 10 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2029-03-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 47,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 9 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,667 shares Expires 2030-02-14 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 8 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 60,000 shares Expires 2031-02-25 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 126,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 7 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126,667 shares Expires 2032-01-05 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 157,500 | Not disclosed Strike: $2.16 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 6 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 157,500 shares Expires 2032-12-06 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 157,500 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 5 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 157,500 shares Expires 2033-03-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | Not disclosed Strike: $0.84 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 4 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2033-11-19 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 375,000 | Not disclosed Strike: $0.97 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 3 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 375,000 shares Expires 2034-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 440,000 | Not disclosed Strike: $1.13 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 2 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 440,000 shares Expires 2035-03-03 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| March 19, 2026 Filed Mar 20, 2026 20:14 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 506,250 | Not disclosed Strike: $2.88 | Not disclosed |
DisclosureSEC source: 0001553179-26-000004 · wk-form4_1774037666.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 506,250 shares Expires 2036-01-01 F1 · kind: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of March 19, 2026 (the "Repricing Date"), the Issuer approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Incentive Award Plan (the "2019 Plan"), which reduced the per share exercise price of each Repriced Option to $0.45 (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| January 30, 2026 Filed Feb 3, 2026 15:00 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 53,960 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034632 · ownership.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,960 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2027. Each restricted stock unit represents a contigent right to receive one share of common stock. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:35 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 506,250 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001553179-26-000002 · wk-form4_1767648900.xml · derivative · entry 4 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 506,250 Underlying: Common Stock · 506,250 shares Expires 2036-01-01 F2 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on January 2, 2027 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 02, 2026 Filed Jan 5, 2026 21:35 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 84,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001553179-26-000002 · wk-form4_1767648900.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 814,061 F1 · shares: Represents restricted stock unit award, which will vest in four equal annual installments in accordance with the terms of the award and subject to the Reporting Person's continuous service to the Issuer on each vesting date. Read SEC document |
| October 01, 2025 Filed Oct 2, 2025 20:13 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 125,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001553179-25-000004 · wk-form4_1759436015.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 710,934 F1 · shares: Represents performance stock unit award, which will vest in full upon the earlier of (i) the approval of a new drug application for seralutinib or (ii) a change in control, in either case on or prior to the fourth anniversary of the grant date, and subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:08 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 440,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001728117-25-000015 · wk-form4_1741295273.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 440,000 Underlying: Common Stock · 440,000 shares Expires 2035-03-03 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 4, 2026 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:23 UTC Amendment | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 35,900 | $0.00 Strike: $1.70 | $0.00 |
DisclosureSEC source: 0000950170-25-013728 · ownership.xml · derivative · entry 2 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-31 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 22:23 UTC Amendment | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 17,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-013728 · ownership.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,130 F1 · shares: The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 16:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 35,900 | $1.73 Strike: $1.73 | $62,107.00 |
DisclosureSEC source: 0000950170-25-012094 · ownership.xml · derivative · entry 2 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,900 Underlying: Common Stock · 35,900 shares Expires 2035-01-30 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 30, 2025 Filed Feb 3, 2025 16:32 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 17,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-012094 · ownership.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,130 F1 · shares: The shares were granted as restricted stock units which vest in full on January 30, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 22:16 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | SaleCommon Stock | 6,430 | $1.16 | $7,429.87 |
DisclosureSEC source: 0001728117-24-000041 · wk-form4_1711664190.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 585,934 F1 · shares: Represents a broker-assisted sale to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. F2 · price: This transaction was executed in multiple trades at prices ranging from $1.1551 to $1.1626 per share. The price reported above reflects the weighted average sale price for the entire number of shares sold. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 83,685 | $0.00 Strike: $2.09 | $0.00 |
DisclosureSEC source: 0001209191-24-001982 · doc4.xml · derivative · entry 2 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 83,685 Underlying: Common Stock · 83,685 shares Expires 2034-01-19 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| January 19, 2024 Filed Jan 20, 2024 02:05 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 13,948 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001982 · doc4.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,180 F1 · shares: The shares were granted as restricted stock units which vest in full on January 19, 2025. Read SEC document |
| January 02, 2024 Filed Jan 4, 2024 22:08 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 375,000 | $0.00 Strike: $0.97 | $0.00 |
DisclosureSEC source: 0001728117-24-000008 · wk-form4_1704406067.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 375,000 Underlying: Common Stock · 375,000 shares Expires 2034-01-01 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on January 2, 2025 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| November 20, 2023 Filed Nov 23, 2023 00:07 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001728117-23-000144 · wk-form4_1700698009.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2033-11-19 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on November 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:01 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock Purchase Warrants · Derivative | 3,376 | $0.13 Strike: $2.04 | $422.00 |
DisclosureSEC source: 0001728117-23-000098 · wf-form4_169040168831720.xml · derivative · entry 4 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 3,376 Underlying: Common Stock · 3,376 shares Expires 2028-07-24 Read SEC document |
| July 24, 2023 Filed Jul 26, 2023 20:01 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantCommon Stock | 13,504 | $1.82 | $24,577.28 |
DisclosureSEC source: 0001728117-23-000098 · wf-form4_169040168831720.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 45,892 Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 126,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 8 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,667 Underlying: Common Stock · 126,667 shares Expires 2032-01-05 F9 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F8 · price: On May 5, 2023, the Issuer canceled an option granted on January 6, 2022. In exchange for the canceled option, the reporting person received 126,667 options to purchase common stock having a lower exercise price with the same vesting terms. F7 · derivative.exercise_date: One-third of the total number of shares subject to the option vested on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 60,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 7 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-25 F9 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F6 · price: On May 5, 2023, the Issuer canceled an option granted on February 25, 2021. In exchange for the canceled option, the reporting person received 60,000 options to purchase common stock having a lower exercise price with the same vesting terms. F5 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 47,667 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 6 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,667 Underlying: Common Stock · 47,667 shares Expires 2030-02-14 F9 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F4 · price: On May 5, 2023, the Issuer canceled an option granted on February 14, 2020. In exchange for the canceled option, the reporting person received 47,667 options to purchase common stock having a lower exercise price with the same vesting terms. F3 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 70,000 | Not disclosed Strike: $1.36 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 5 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-03-25 F9 · derivative.exercise_price: The exercise price of the option is $1.36 per share, representing the fair market value per share of the Issuer's common stock on the date of grant; provided that in the event the option is exercised prior to May 5, 2024, or the Reporting Person's employment terminates prior to May 5, 2024 other than due to death, disability or circumstances giving rise to severance under the Reporting Person's employment agreement, the exercise price will be increased to the exercise price of the cancelled option in exchange for which this option was granted. F2 · price: On May 5, 2023, the Issuer canceled an option granted on March 25, 2019. In exchange for the canceled option, the reporting person received 70,000 options to purchase common stock having a lower exercise price with the same vesting terms. F1 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 190,000 | Not disclosed Strike: $11.94 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 4 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 190,000 shares Expires 2032-01-05 F8 · price: On May 5, 2023, the Issuer canceled an option granted on January 6, 2022. In exchange for the canceled option, the reporting person received 126,667 options to purchase common stock having a lower exercise price with the same vesting terms. F7 · derivative.exercise_date: One-third of the total number of shares subject to the option vested on January 6, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 90,000 | Not disclosed Strike: $9.79 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 3 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 90,000 shares Expires 2031-02-25 F6 · price: On May 5, 2023, the Issuer canceled an option granted on February 25, 2021. In exchange for the canceled option, the reporting person received 60,000 options to purchase common stock having a lower exercise price with the same vesting terms. F5 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 25, 2022 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 71,500 | Not disclosed Strike: $14.55 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 2 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,500 shares Expires 2030-02-14 F4 · price: On May 5, 2023, the Issuer canceled an option granted on February 14, 2020. In exchange for the canceled option, the reporting person received 47,667 options to purchase common stock having a lower exercise price with the same vesting terms. F3 · derivative.exercise_date: 25% of the total number of shares subject to the option vested on February 14, 2021 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| May 05, 2023 Filed May 9, 2023 20:18 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | Disposition to issuerStock Option (Right to Buy) · Derivative | 105,000 | Not disclosed Strike: $22.10 | Not disclosed |
DisclosureSEC source: 0001728117-23-000055 · wf-form4_168366350375181.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 105,000 shares Expires 2029-03-25 F2 · price: On May 5, 2023, the Issuer canceled an option granted on March 25, 2019. In exchange for the canceled option, the reporting person received 70,000 options to purchase common stock having a lower exercise price with the same vesting terms. F1 · derivative.exercise_date: The shares subject to the option are fully vested. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 21:19 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 157,500 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001728117-23-000022 · wf-form4_167951991888150.xml · derivative · entry 4 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2033-03-19 F1 · derivative.exercise_date: 25% of the total number of shares subject to the option will vest on March 20, 2024 and 1/48th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| March 20, 2023 Filed Mar 22, 2023 21:19 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | PurchaseCommon Stock | 18,500 | $1.20 | $22,144.50 |
DisclosureSEC source: 0001728117-23-000022 · wf-form4_167951991888150.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: No plan indicated Ownership: Indirect · By family trust Disclosed balance after: 32,388 Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 77,160 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-22-062192 · doc4.xml · derivative · entry 2 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,160 Underlying: Common Stock · 77,160 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:22 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 38,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062192 · doc4.xml · nonDerivative · entry 1 Christian Waage · CIK 0001553179 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,232 F1 · shares: The shares were granted as restricted stock units which vest in full on December 16, 2023. Read SEC document |
| December 07, 2022 Filed Dec 9, 2022 22:17 UTC | Gossamer Bio, Inc. GOSS · Entity 6928 | GrantStock Option (Right to Buy) · Derivative | 157,500 | $0.00 Strike: $2.16 | $0.00 |
DisclosureSEC source: 0001728117-22-000108 · wf-form4_167062422822547.xml · derivative · entry 1 Christian Waage · CIK 0001553179 · EVP, Tech Ops and Admin 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,500 Underlying: Common Stock · 157,500 shares Expires 2032-12-06 F1 · derivative.exercise_date: One-third of the total number of shares subject to the option will vest on December 7, 2023 and 1/36th of the total number of shares subject to the option vest on the last day of each one-month period thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.